Schrödinger discontinued development of its CDC7 inhibitor SGR-2921 following the deaths of two acute myeloid leukemia patients in a phase 1 trial, with one death linked to the therapy due to acute liver failure. Despite initial optimism based on pharmacological data, the therapy’s benefit-risk profile and safety concerns led to termination of further investigation. The company continues development of other oncology candidates, including MALT1 and Wee1/Myt1 inhibitors.